ABBISKO CAYMAN DL-00001 (8ZD) - Total Assets
Based on the latest financial reports, ABBISKO CAYMAN DL-00001 (8ZD) holds total assets worth €2.35 Billion EUR (≈ $2.75 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ABBISKO CAYMAN DL-00001 shareholders equity for net asset value and shareholders' equity analysis.
ABBISKO CAYMAN DL-00001 - Total Assets Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's total assets have evolved over time, based on quarterly financial data. Check 8ZD asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
ABBISKO CAYMAN DL-00001 - Asset Composition Analysis
Current Asset Composition (December 2025)
ABBISKO CAYMAN DL-00001's total assets of €2.35 Billion consist of 90.4% current assets and 9.6% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 31.8% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €4.20 Million | 0.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how ABBISKO CAYMAN DL-00001's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of ABBISKO CAYMAN DL-00001.
Key Asset Composition Facts
- Current vs. Non-Current Assets: ABBISKO CAYMAN DL-00001's current assets represent 90.4% of total assets in 2025, a decrease from 97.2% in 2021.
- Cash Position: Cash and equivalents constituted 31.8% of total assets in 2025, down from 95.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 0.2% of total assets.
ABBISKO CAYMAN DL-00001 Competitors by Total Assets
Key competitors of ABBISKO CAYMAN DL-00001 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.82 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $146.48 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩130.74 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥772.57 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥773.72 Million |
ABBISKO CAYMAN DL-00001 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.98 | 14.92 | 21.75 |
| Quick Ratio | 4.98 | 14.92 | 21.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.70 Billion | €1.88 Billion | €2.09 Billion |
ABBISKO CAYMAN DL-00001 - Advanced Valuation Insights
This section examines the relationship between ABBISKO CAYMAN DL-00001's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.36 |
| Latest Market Cap to Assets Ratio | 0.34 |
| Asset Growth Rate (YoY) | 11.7% |
| Total Assets | €2.35 Billion |
| Market Capitalization | $809.57 Million USD |
Valuation Analysis
Below Book Valuation: The market values ABBISKO CAYMAN DL-00001's assets below their book value (0.34x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: ABBISKO CAYMAN DL-00001's assets grew by 11.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for ABBISKO CAYMAN DL-00001 (2021–2025)
The table below shows the annual total assets of ABBISKO CAYMAN DL-00001 from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €2.35 Billion ≈ $2.75 Billion |
+11.68% |
| 2024-12-31 | €2.11 Billion ≈ $2.46 Billion |
-0.39% |
| 2023-12-31 | €2.12 Billion ≈ $2.47 Billion |
-15.03% |
| 2022-12-31 | €2.49 Billion ≈ $2.91 Billion |
-6.22% |
| 2021-12-31 | €2.65 Billion ≈ $3.10 Billion |
-- |
About ABBISKO CAYMAN DL-00001
Abbisko Cayman Limited engages in the research and development of pharmaceutical products in the People's Republic of China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor in NDA/commercial trial for the treatment of tenosynovial giant cell tumors, as well as chronic graft versus host disease and solid tumors. It is also developing pivotal tri… Read more